Indications and procedure for CAR T-cell infusion Article à paraître

  • [1] Maude S.L., Laetsch T.W., Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439-448.
  • [2] Neelapu S.S., Rossi J.M., Jacobson C.A. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. Blood. 2019;134:203. Supplement_1
  • [3] Schuster S.J., Bishop M.R., Tam C.S. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56. 1
  • [4] Abramson J.S., Palomba M.L., Gordon L.I. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019;134:241. Supplement_1
  • [5] Haute Autorité de Santé (HAS). Kymriah (tisagenlecleucel), CAR T anti-CD19 (LAL). HAS, 2019.
  • [6] HAS. Kymriah (tisagenlecleucel), CAR T anti-CD19 (LDGCB). HAS, 2019.
  • [7] HAS. Yescarta (axicabtagene ciloleucel), CAR T anti-CD19. HAS, 2020.
  • [8] European Medicines Agency. Yescarta. European Medicines Agency, 2018.
  • [9] European Medicines Agency. Kymriah. European Medicines Agency, 2018.
  • [10] Paillassa J., Di Blasi R., Chevret S. CD19 CAR T-cell therapy in patients with relapse/refractory DLBCL: retrospective analysis of the eligibility criteria. Blood. 2019;134:2887. Supplement_1
  • [11] Neelapu S.S., Locke F.L., Bartlett N.L. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-2544. 26
  • [12] Yakoub-Agha I., Chabannon C., Bader P. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105:297-316. 2
  • [13] Thieblemont C., Le Gouill S., Di Blasi R. Real-world results on CD19 CAR T-cell for 60 french patients with relapsed/refractory diffuse large B-cell lymphoma included in a temporary authorization for use program. EHA. 2019;37:301. S2
  • [14] Paillassa J., Vercellino L., Di Blasi R. Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse/refractory diffuse large B-cell lymphoma in real world experience. Blood. 2019;134:2886. Supplement_1
  • [15] Turtle C.J., Hanafi L.-A., Berger C. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116. 355
  • [16] Novartis. CTL019 Train. Sess. Plan Gest. des risques, Version 2.0. 2019.
  • [17] Norelli M., Camisa B., Barbiera G. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739-748. 6
  • [18] Sterner R.M., Sakemura R., Cox M.J. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697-709. 7
  • [19] Hay K.A., Hanafi L.-A., Li D. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295-2306. 21
  • [20] Lee D.W., Santomasso B.D., Locke F.L. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638. 4
  • [21] Gust J., Hay K.A., Hanafi L.-A. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404-1419. 12
  • [22] Liu S., Deng B., Yin Z. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10:15. 2
  • [23] Fried S., Avigdor A., Bielorai B. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643-1650. 10
  • [24] Dunleavy K., Hakim F., Kim H.K. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106:795-802. 3
  • [25] Hill J.A., Li D., Hay K.A. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131:121-130. 1
  • [26] Park J.H., Romero F.A., Taur Y. Cytokine release syndrome grade is a predictive marker for infections in relapsed or refractory B-cell all patients treated with CAR T cells. Clin Infect Dis. 2018;67:1-8. 4